Table 3.

Incidence rates of venous thromboembolism in all baricitinib rheumatoid arthritis studies (ALL BARI RA) and of rheumatoid arthritis patient databases (IMEDS and Truven) who did not use baricitinib

Age groups	ALL BARI RA (n = 3492)	IMEDS (n = 69,095)	Truven (n = 205,785)
18–49	0.14 (0.04–0.35)	0.49 (0.37–0.63)	0.50
50–59	0.57 (0.32–0.95)	0.90 (0.75–1.07)	0.77
60–64	0.77 (0.35–1.47)	1.16 (0.93–1.43)	1.05
≥ 65	1.09 (0.59–1.83)	2.13 (1.94–2.33)	2.16
All ages	0.53 (0.38–0.71)	1.34 (1.24–1.44)	1.05 (1.01–1.09)

Data are presented as number per 100 person-years (95% CI). The Truven data do not include 95% CIs by age groups [44]

CI confidence interval, IMEDS Innovation in Medical Evidence Development and Surveillance, Truven Truven health marketscan commercial claims and encounters databases